{"product_id":"european-association-of-dermato-oncology-16th-european-post-chicago-melanoma","title":"European Association of Dermato-Oncology 16th European Post-Chicago Melanoma Skin Cancer Meeting 2026","description":"\u003cdiv id=\"bylineInfo\" class=\"a-section a-spacing-micro bylineHidden feature\"\u003e\r\n\u003ch3 class=\"product_title entry-title\"\u003eEuropean Association of Dermato-Oncology 16th European Post-Chicago Melanoma Skin Cancer Meeting 2026\u003c\/h3\u003e\r\n\u003cstrong\u003e+ Target Audience: dermatologists, oncologists, surgeons, and other healthcare professionals\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-938\" data-path-to-node=\"0\"\u003e\u003cspan data-path-to-node=\"0,0\"\u003eThe 16th European Post-Chicago Melanoma\/Skin Cancer Meeting (EPCM) will be held from June 25th-26th, 2026, at the Radisson Blu Hotel in Hamburg, Germany\u003c\/span\u003e\u003cspan data-path-to-node=\"0,2\"\u003e. Organized under the auspices of the Melanoma World Society (MWS) and the European Association of Dermato Oncology (EADO), this interdisciplinary global conference aims to present emerging developments in melanoma and skin cancer diagnostics and therapy\u003c\/span\u003e\u003cspan data-path-to-node=\"0,4\"\u003e. The program features international key opinion leaders sharing their latest research, clinical trial results, and insights from the recent ASCO meeting\u003c\/span\u003e\u003cspan data-path-to-node=\"0,6\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003cp data-path-to-node=\"1\"\u003e\u003cb data-path-to-node=\"1\" data-index-in-node=\"0\"\u003eLearning Objectives\u003c\/b\u003e\u003c\/p\u003e\r\n\u003cp data-path-to-node=\"1\"\u003eAfter completing this activity, participants should be better able to:\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"2\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-939\" data-path-to-node=\"2,0,0\"\u003e\u003cspan data-path-to-node=\"2,0,0,0\"\u003eEvaluate the latest highlights from ASCO 2026 regarding melanoma and non-melanoma skin cancer\u003c\/span\u003e\u003cspan data-path-to-node=\"2,0,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-940\" data-path-to-node=\"2,1,0\"\u003e\u003cspan data-path-to-node=\"2,1,0,0\"\u003eUnderstand the role of dermoscopy in detecting all types of skin cancers\u003c\/span\u003e\u003cspan data-path-to-node=\"2,1,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-941\" data-path-to-node=\"2,2,0\"\u003e\u003cspan data-path-to-node=\"2,2,0,0\"\u003eAssess how lifestyle factors, such as exercise, nutrition, and timing of ICI administration, impact cancer treatment outcomes\u003c\/span\u003e\u003cspan data-path-to-node=\"2,2,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-942\" data-path-to-node=\"2,3,0\"\u003e\u003cspan data-path-to-node=\"2,3,0,0\"\u003eReview updates from various melanoma registries and databases across Europe\u003c\/span\u003e\u003cspan data-path-to-node=\"2,3,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-943\" data-path-to-node=\"2,4,0\"\u003e\u003cspan data-path-to-node=\"2,4,0,0\"\u003eManage treatments for vulnerable skin cancer populations, including frail, immunocompromised, and family-planning patients\u003c\/span\u003e\u003cspan data-path-to-node=\"2,4,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-944\" data-path-to-node=\"2,5,0\"\u003e\u003cspan data-path-to-node=\"2,5,0,0\"\u003eApply gene expression profiling (GEP) in melanoma management and interpret the 2026 EADO guidelines for basal cell and cutaneous squamous cell carcinomas\u003c\/span\u003e\u003cspan data-path-to-node=\"2,5,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-945\" data-path-to-node=\"2,6,0\"\u003e\u003cspan data-path-to-node=\"2,6,0,0\"\u003eEvaluate the role of ImmTACs (bi-specific agents) for metastatic uveal and cutaneous melanomas, and discuss the management of melanoma brain metastases\u003c\/span\u003e\u003cspan data-path-to-node=\"2,6,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-946\" data-path-to-node=\"2,7,0\"\u003e\u003cspan data-path-to-node=\"2,7,0,0\"\u003eAssess the existence of the abscopal effect of radiotherapy and current strategies for adjuvant and neoadjuvant melanoma treatments\u003c\/span\u003e\u003cspan data-path-to-node=\"2,7,0,2\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-path-to-node=\"3\"\u003e\u003cb data-path-to-node=\"3\" data-index-in-node=\"0\"\u003eTarget Audience\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli data-path-to-node=\"3\"\u003eThis educational activity is intended for dermatologists, oncologists, surgeons, and other healthcare professionals involved in the diagnosis, treatment, and research of melanoma and non-melanoma skin cancers.\u003c\/li\u003e\r\n \t\u003cli data-path-to-node=\"3\"\u003eBest for Dermatologists, Medical Oncologists, Surgical Oncologists, and Radiation Oncologists.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-path-to-node=\"4\"\u003e\u003cb data-path-to-node=\"4\" data-index-in-node=\"0\"\u003eTopics\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,0,0\"\u003e\u003cb data-path-to-node=\"5,0,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM I: My personal highlights at ASCO 2026\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,0,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-947\" data-path-to-node=\"5,0,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,0,1,0,0,0\"\u003ein melanoma\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-948\" data-path-to-node=\"5,0,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,0,1,1,0,0\"\u003ein non-melanoma skin cancer\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-949\" data-path-to-node=\"5,1,0\"\u003e\u003cspan data-path-to-node=\"5,1,0,0\"\u003e\u003cb data-path-to-node=\"5,1,0,0\" data-index-in-node=\"0\"\u003eKEYNOTE LECTURE I:\u003c\/b\u003e Dermoscopy for the detection of all skin cancers?!\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,2,0\"\u003e\u003cb data-path-to-node=\"5,2,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM II: Lifestyle factors impacting cancer treatment outcomes\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,2,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-950\" data-path-to-node=\"5,2,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,2,1,0,0,0\"\u003eExercise\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-951\" data-path-to-node=\"5,2,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,2,1,1,0,0\"\u003eNutrition\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-952\" data-path-to-node=\"5,2,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,2,1,2,0,0\"\u003eTiming of ICI administration\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,4,0\"\u003e\u003cb data-path-to-node=\"5,4,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM III: Merkel Cell Carcinoma\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,4,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-954\" data-path-to-node=\"5,4,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,4,1,0,0,0\"\u003eAdjuvant and neoadjuvant trials\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-955\" data-path-to-node=\"5,4,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,4,1,1,0,0\"\u003eRole of irradiation for MCC\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-956\" data-path-to-node=\"5,4,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,4,1,2,0,0\"\u003eTreatment for advanced MCC\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,6,0\"\u003e\u003cb data-path-to-node=\"5,6,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM IV: Treatment of vulnerable skin cancer patients\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,6,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-964\" data-path-to-node=\"5,6,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,6,1,0,0,0\"\u003eFamily planning\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-965\" data-path-to-node=\"5,6,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,6,1,1,0,0\"\u003eOld and frail patients\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-966\" data-path-to-node=\"5,6,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,6,1,2,0,0\"\u003eImmunocompromised patients\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,8,0\"\u003e\u003cb data-path-to-node=\"5,8,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM V: Adverse event management for ICI\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,8,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-970\" data-path-to-node=\"5,8,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,8,1,0,0,0\"\u003eLong-term toxicities \/ delayed onset toxicities\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-971\" data-path-to-node=\"5,8,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,8,1,1,0,0\"\u003eICI rechallenge after immune-related adverse events\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-972\" data-path-to-node=\"5,8,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,8,1,2,0,0\"\u003eWhat you should know about differences of various immunosuppressants\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,9,0\"\u003e\u003cb data-path-to-node=\"5,9,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM VI: GEP – Gene expression profiling\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,9,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-973\" data-path-to-node=\"5,9,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,9,1,0,0,0\"\u003eWhich test is the best for melanoma?\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-974\" data-path-to-node=\"5,9,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,9,1,1,0,0\"\u003eWhat can we learn from Breast Cancer (Oncotype DX Test)?\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-975\" data-path-to-node=\"5,9,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,9,1,2,0,0\"\u003eHow to implement GEP in melanoma guidelines?\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,11,0\"\u003e\u003cb data-path-to-node=\"5,11,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM VII: EADO guidelines 2026 for various skin cancers: What’s new?\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,11,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-977\" data-path-to-node=\"5,11,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,11,1,0,0,0\"\u003e…basal cell carcinoma (BCC)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-978\" data-path-to-node=\"5,11,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,11,1,1,0,0\"\u003e…cutaneous squamous cell carcinoma (CSCC)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-979\" data-path-to-node=\"5,11,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,11,1,2,0,0\"\u003e…current trials for BCC\/CSCC with future implications\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,13,0\"\u003e\u003cb data-path-to-node=\"5,13,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM VIII: ImmTACs: novel bi-specific agents for metastatic uveal and cutaneous melanomas\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,13,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-984\" data-path-to-node=\"5,13,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,13,1,0,0,0\"\u003eTreatment of metastatic ocular melanoma: it’s a whole new world!\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-985\" data-path-to-node=\"5,13,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,13,1,1,0,0\"\u003eTebentafusp, Brenetafusp and other ImmTACs not only for uveal melanoma\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-986\" data-path-to-node=\"5,14,0\"\u003e\u003cspan data-path-to-node=\"5,14,0,0\"\u003e\u003cb data-path-to-node=\"5,14,0,0\" data-index-in-node=\"0\"\u003eKEYNOTE LECTURE II:\u003c\/b\u003e Personalized oncology: already reality or just a dream?\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-987\" data-path-to-node=\"5,15,0\"\u003e\u003cspan data-path-to-node=\"5,15,0,0\"\u003e\u003cb data-path-to-node=\"5,15,0,0\" data-index-in-node=\"0\"\u003eKEYNOTE LECTURE III:\u003c\/b\u003e Neoadjuvant or perioperative treatment for melanoma?\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-988\" data-path-to-node=\"5,16,0\"\u003e\u003cspan data-path-to-node=\"5,16,0,0\"\u003e\u003cb data-path-to-node=\"5,16,0,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM IX: Is the abscopal effect of radiotherapy existing?\u003c\/b\u003e (Yes \/ No Panel Discussion)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,17,0\"\u003e\u003cb data-path-to-node=\"5,17,0\" data-index-in-node=\"0\"\u003eSYMPOSIUM X: Adjuvant treatment of melanoma\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,17,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-989\" data-path-to-node=\"5,17,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,17,1,0,0,0\"\u003eTargeted therapy or immune checkpoint inhibition for BRAF mutated stage III patients?\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-990\" data-path-to-node=\"5,17,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,17,1,1,0,0\"\u003eIs combo immune checkpoint inhibition replacing single agent anti-PD1?\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-991\" data-path-to-node=\"5,17,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,17,1,2,0,0\"\u003eHow long is long enough?\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"5,18,0\"\u003e\u003cb data-path-to-node=\"5,18,0\" data-index-in-node=\"0\"\u003eSatellite Symposia:\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"5,18,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-992\" data-path-to-node=\"5,18,1,0,0\"\u003e\u003cspan data-path-to-node=\"5,18,1,0,0,0\"\u003eNuances in Metastatic Uveal Melanoma Care A Global Dialogue on current Clinical Practice, Treatment Algorithms and Emerging Insights\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-993\" data-path-to-node=\"5,18,1,1,0\"\u003e\u003cspan data-path-to-node=\"5,18,1,1,0,0\"\u003eAdvancing Treatment Pathways in Cutaneous Squamous Cell Carcinoma: Patients to Practice\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-994\" data-path-to-node=\"5,18,1,2,0\"\u003e\u003cspan data-path-to-node=\"5,18,1,2,0,0\"\u003eEarly-Stage Melanoma in Daily Practice: Are We Ready for Individualized Therapy?\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-995\" data-path-to-node=\"5,18,1,3,0\"\u003e\u003cspan data-path-to-node=\"5,18,1,3,0,0\"\u003eRedefining Melanoma Care 2026: Innovation, Evidence, Outcomes\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp id=\"p-rc_299540cfc679521b-996\" data-path-to-node=\"5,18,1,4,0\"\u003e\u003cspan data-path-to-node=\"5,18,1,4,0,0\"\u003eImmune checkpoint inhibitors in Merkel cell carcinoma: 10 years of progress from 2016 to 2026\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e","brand":"Meducourse","offers":[{"title":"Default Title","offer_id":43163712847970,"sku":"MED-AMB09729","price":60.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/European-Association-of-Dermato-Oncology-16th-European-Post-Chicago-Melanoma-Skin-Cancer-Meeting-2026.jpg?v=1785419573","url":"https:\/\/meducourse.com\/products\/european-association-of-dermato-oncology-16th-european-post-chicago-melanoma","provider":"Meducourse","version":"1.0","type":"link"}